1-Ginsberg MD, Palesch YY, Hill MD. The ALIAS (ALbumin In Acute Stroke) phase III randomized multicentre clinical trial: design and progress report. Biochem Soc Trans 2006;34(Pt 6):1323-6.
3-Thom TJ. Stroke mortality trends. An international perspective. Ann Epidemiol 1993;3(5):509–18.
4-Fogelholm R, Nuutila M, Vuorela AL. Primary intracerebral haemorrhage in the Jyväskylä region, central Finland, 1985–89: incidence, case fatality rate, and functional outcome. J Neurol Neurosurg Psychiatry 1992;55(7):546–52.
5-Belayev L, Saul I, Busto R, Danielyan K, Vigdorchik A, Khoutorova L, et al. Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. Stroke 2005;36(2):326-31.
6-Broderick JP, Brott T, Tomsick T, Huster G, Miller R. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med 1992;326(11):733-6.
7-Belayev L, Pinard E, Nallet H,
Seylaz J,
Liu Y,
Riyamongkol P, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 2002;33(4):1077–84.
8-Dziedzic T, Pera J, Slowik A, Gryz-Kurek EA, Szczudlik A. Hypoalbuminemia in acute ischemic stroke patients: frequency and correlates.
Eur J Clin Nutr 2007;61(11):1318-22.
10-
Belayev L,
Liu Y,
Zhao W,
Busto R,
Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32(2):553- 60
11-Suarez J, Shannon L,
Zaidat OO,
Suri MF,
Singh G,
Lynch G,
et al. Effect of human albumin administration on clinical outcome and hospital cost in paitents with subarachnoid hemorrhage.
J Neurosurg 2004;100(4):585-90.
12-Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect ofdelayed albumin hemodilution on infarction volume and brain edemaafter transient middle cerebral artery occlusion in rats. J Neurosurg 1997;87:595–601.
13-Belayev L, Zhao W, Pattany PM, Weaver RG, Huh PW, Lin B, et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke 1998;29(12):2587–99.
14-Liu Y, Belayev L, Zhao W, Busto R, Belayev A, Ginsberg MD. Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur J Pharmacol 2001;428(2):193–201.
15-Belayev L, Saul I, Huh PW, Finotti N, Zhao W, Busto R, et al. Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats. Brain Res 1999;845(1):107–11.
16-Belayev L, Alonso OF, Huh PW, Zhao W, Busto R, Ginsberg MD. Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injuryin rats. J Neurotrauma 1999;16(6):445–53.
17-Giroud M, Gras P, Chadan N,
Beuriat P,
Milan C,
Arveux P, et al. Cerebral haemorrhage in a French prospective population study. J Neurol Neurosurg Psychiatry1991;54(7):595-8.
18-Thrift AG, Mc Neil JJ, Forbes A, Donnan GA. Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension 1998;31(6):1223-9.
19-Wagner KR, Xi G, Hua Y, Kleinholz M, de Courten-Myers GM, Myers RE. Early metabolic alterations in edematous perihematomal brain regions following experimental intracerebral hemorrhage. J Neurosurg 1998;88(6):1058-65.
20-Hickenbottom SL, Grotta JC, Strong R, Denner LA, Aronowski J. Nuclear factor-kappaB and cell death after experimental intracerebral hemorrhage in rats. Stroke 1999;30(11):2472-7.